ANTIBODIES TO BOTH RO52 AND RO60 DEFINE A SUBSET OF SJOGREN'S MOST SUITABLE FOR CLINICAL TRIALS OF AGENTS TARGETING LYMPHOPROLIFERATIONS


Creative Commons License

ARMAĞAN B., Robinson S., Bazoberry A., Grader-Beck T., Baer A.

Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.1160, (Summary Text) identifier